{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:29:50Z","timestamp":1773188990992,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T00:00:00Z","timestamp":1690156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Hainan Provincial Postgraduate Innovation Research Project","award":["Qhyb2022-133"],"award-info":[{"award-number":["Qhyb2022-133"]}]},{"name":"Hainan Province Clinical Medical Center","award":["No. 2021818"],"award-info":[{"award-number":["No. 2021818"]}]},{"name":"scientific research projects of academician innovation platform in Hainan Province","award":["00817378"],"award-info":[{"award-number":["00817378"]}]},{"name":"the specific research fund of The Innovation Platform for Academicians of Hainan Province","award":["No.2022136"],"award-info":[{"award-number":["No.2022136"]}]},{"name":"Hainan Provincial Health Industry Research Project","award":["22A200078"],"award-info":[{"award-number":["22A200078"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>This study aimed to evaluate the efficacy, adverse events, patient compliance, and cost of dual therapy with Ilaprazole-amoxicillin (IA) at high dose versus Ilaprazole-amoxicillin-furazolidone-bismuth (IAFB) quadruple therapy for the Helicobacter pylori (<jats:italic>H.pylori<\/jats:italic>) infection among Chinese patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>200 patients who had tested positive for <jats:italic>H. pylori<\/jats:italic> and undergoing upper gastrointestinal endoscopy after being diagnosed with chronic gastritis participated in this open-label randomized controlled clinical trial. Patients were randomized to Group A and Group B: the 14-day IA dual treatment group (101) and IAFB quadruple treatment group (99). The <jats:sup>13<\/jats:sup>\u00a0C urea breath test was conducted to determine whether <jats:italic>H. pylori<\/jats:italic> had been eliminated 4\u20136 weeks after the treatment. Eradication rates, drug-related adverse events, patient compliance, and drug costs were compared between the two treatment groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eradication rates in group A were 92.1% and 94.9%, depending on the intention-to-treat (ITT), per-protocol (PP), respectively, which was similar to group B (91.9% and 93.6%). There was no significant difference observed in adverse events between the two groups (<jats:italic>P<\/jats:italic>\u2009=\u20090.518). Interestingly, compliance was significantly higher in group A compared to the group B (<jats:italic>P<\/jats:italic>\u2009=\u20090.031). In addition, drug costs were significantly lower for group A in comparison to the group B.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>IA dual therapy was found to be equally effective, safer and less costly than IAFB quadruple therapy. Therefore, these therapies can be potentially considered as first-line regimens for empirical treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12876-023-02890-5","type":"journal-article","created":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T08:02:33Z","timestamp":1690185753000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Ilaprazole-amoxicillin dual therapy at high dose as a first-line treatment for helicobacter pylori infection in Hainan: a single-center, open-label, noninferiority, randomized controlled trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Xiao-Dong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da-Ya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6133-8919","authenticated-orcid":false,"given":"Run-Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Ju","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shi-Mei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei-Hu","family":"Bai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,24]]},"reference":[{"key":"2890_CR1","first-page":"gutjnl","volume":"8","author":"P Malfertheiner","year":"2022","unstructured":"Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou JM, Schulz C, et al. European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: the Maastricht VI\/Florence consensus report. Gut. 2022;8:gutjnl\u20132022.","journal-title":"Gut"},{"issue":"1","key":"2890_CR2","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.gastro.2016.04.006","volume":"151","author":"CA Fallone","year":"2016","unstructured":"Fallone CA, Chiba N, Zanten SV, Fischbach L, Gisbert JP, Hunt RH, et al. The Toronto Consensus for the treatment of Helicobacter pylori infection in adults. Gastroenterology. 2016;151(1):51\u201369e14.","journal-title":"Gastroenterology"},{"issue":"5","key":"2890_CR3","first-page":"289","volume":"42","author":"The Helicobacter pylori Group of the Chinese Medical Association, Gastroenterology Branch","year":"2022","unstructured":"The Helicobacter pylori Group of the Chinese Medical Association, Gastroenterology Branch. Sixth national consensus report on the management of Helicobacter pylori infection (non-elimination treatment part). Chin J Gastroenterol. 2022;42(5):289\u2013303.","journal-title":"Chin J Gastroenterol"},{"issue":"2","key":"2890_CR4","doi-asserted-by":"publisher","first-page":"e12475","DOI":"10.1111\/hel.12475","volume":"23","author":"WZ Liu","year":"2018","unstructured":"Liu WZ, Xie Y, Lu H, Cheng H, Zeng ZR, Zhou LY, et al. Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter. 2018;23(2):e12475.","journal-title":"Helicobacter"},{"issue":"7","key":"2890_CR5","doi-asserted-by":"publisher","first-page":"e14396","DOI":"10.1097\/MD.0000000000014396","volume":"98","author":"X Yang","year":"2019","unstructured":"Yang X, Wang JX, Han SX, Gao CP. High dose dual therapy versus bismuth quadruple therapy for Helicobacter pylori eradication treatment: a systematic review and meta-analysis. Medicine. 2019;98(7):e14396.","journal-title":"Medicine"},{"issue":"4","key":"2890_CR6","doi-asserted-by":"publisher","first-page":"e12692","DOI":"10.1111\/hel.12692","volume":"25","author":"CP Gao","year":"2020","unstructured":"Gao CP, Zhang D, Zhang T, Wang JX, Han SX, Graham DY, et al. PPI-amoxicillin dual therapy for Helicobacter pylori infection: an update based on a systematic review and meta-analysis. Helicobacter. 2020;25(4):e12692.","journal-title":"Helicobacter"},{"issue":"10","key":"2890_CR7","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1097\/MCG.0000000000001448","volume":"55","author":"Q Huang","year":"2021","unstructured":"Huang Q, Shi Z, Cheng H, Ye H, Zhang X. Efficacy and safety of modified dual therapy as the first-line regimen for the treatment of Helicobacter pylori infection: a Meta-analysis of Randomized controlled trials. J Clin Gastroenterol. 2021;55(10):856\u201364.","journal-title":"J Clin Gastroenterol"},{"issue":"3","key":"2890_CR8","doi-asserted-by":"publisher","first-page":"278","DOI":"10.3109\/00498254.2011.622416","volume":"42","author":"KA Seo","year":"2012","unstructured":"Seo KA, Lee SJ, Kim KB, Bae SK, Liu KH, Kim DH, et al. Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5. Xenobiotica. 2012;42(3):278\u201384.","journal-title":"Xenobiotica"},{"issue":"11","key":"2890_CR9","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1111\/bcp.14076","volume":"85","author":"H Wang","year":"2019","unstructured":"Wang H, Shao F, Liu X, Xu W, Ou N, Qin X, et al. Efficacy, safety and pharmacokinetics of ilaprazole infusion in healthy subjects and patients with esomeprazole as positive control. Br J Clin Pharmacol. 2019;85(11):2547\u201358.","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"2890_CR10","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1067\/mcp.2000.109155","volume":"68","author":"AP Periclou","year":"2000","unstructured":"Periclou AP, Goldwater R, Lee SM, Park DW, Kim DY, Cho KD, et al. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease. Clin Pharmacol Ther. 2000;68(3):304\u201311.","journal-title":"Clin Pharmacol Ther"},{"key":"2890_CR11","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ejpb.2020.01.015","volume":"149","author":"T Shen","year":"2020","unstructured":"Shen T, Jiang X, Jin Z, Ji Q, Li C, Li Q, et al. The study of intestinal absorption and biodistribution in vivo of proton pump inhibitors. Eur J Pharm Biopharm. 2020;149:135\u201344.","journal-title":"Eur J Pharm Biopharm"},{"key":"2890_CR12","doi-asserted-by":"publisher","first-page":"771876","DOI":"10.3389\/fphar.2022.771876","volume":"13","author":"M Niu","year":"2022","unstructured":"Niu M, Zhou Y, Xie Y, Li X, Tian Y, Yao L, et al. Comparison of the dual therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth glycyrrhizinate for eradication of Helicobacter pylori. Front Pharmacol. 2022;13:771876.","journal-title":"Front Pharmacol"},{"issue":"7","key":"2890_CR13","first-page":"432","volume":"74","author":"Y Jin","year":"2019","unstructured":"Jin Y, Zhang S, Pan J, Yue M, Zhang G, Yao D, et al. Comparison of efficacy and safety of ilaprazole and esomeprazole both in initial treatment regimen and retreatment regimen of Helicobacter pylori infection in chronic gastritis. Pharmazie. 2019;74(7):432\u20138.","journal-title":"Pharmazie"},{"issue":"5","key":"2890_CR14","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/j.cgh.2014.10.036","volume":"13","author":"JC Yang","year":"2015","unstructured":"Yang JC, Lin CJ, Wang HL, Chen JD, Kao JY, Shun CT, et al. High-dose dual therapy is superior to standard first-line or rescue therapy for Helicobacter pylori infection. Clin Gastroenterol Hepatol. 2015;13(5):895\u2013905e5.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"2890_CR15","doi-asserted-by":"publisher","first-page":"e12762","DOI":"10.1111\/hel.12762","volume":"25","author":"Z Song","year":"2020","unstructured":"Song Z, Zhou L, Xue Y, Suo B, Tian X, Niu Z. A comparative study of 14-day dual therapy (esomeprazole and amoxicillin four times daily) and triple plus bismuth therapy for first-line Helicobacter pylori infection eradication: a randomized trial. Helicobacter. 2020;25(6):e12762.","journal-title":"Helicobacter"},{"issue":"1","key":"2890_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1053\/j.gastro.2018.09.054","volume":"156","author":"J Butt","year":"2019","unstructured":"Butt J, Varga MG, Blot WJ, Teras L, Visvanathan K, Le Marchand L, et al. Serologic response to Helicobacter pylori proteins associated with risk of colorectal cancer among diverse populations in the United States. Gastroenterology. 2019;156(1):175\u201386e2.","journal-title":"Gastroenterology"},{"key":"2890_CR17","doi-asserted-by":"publisher","first-page":"1096103","DOI":"10.3389\/fphar.2023.1096103","volume":"14","author":"Q Yang","year":"2023","unstructured":"Yang Q, He C, Hu Y, Hong J, Zhu Z, Xie Y, et al. 14-day pantoprazole-and amoxicillin-containing high-dose dual therapy for Helicobacter pylori eradication in elderly patients: a prospective, randomized controlled trial. Front Pharmacol. 2023;14:1096103.","journal-title":"Front Pharmacol"},{"issue":"5","key":"2890_CR18","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1053\/j.gastro.2018.07.007","volume":"155","author":"A Savoldi","year":"2018","unstructured":"Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology. 2018;155(5):1372\u201382e17.","journal-title":"Gastroenterology"},{"issue":"4","key":"2890_CR19","doi-asserted-by":"publisher","first-page":"e12816","DOI":"10.1111\/hel.12816","volume":"26","author":"C Li","year":"2021","unstructured":"Li C, Shi Y, Suo B, Tian X, Zhou L, Song Z. PPI-amoxicillin dual therapy four times daily is superior to guidelines recommended regimens in the Helicobacter pylori eradication therapy within Asia: a systematic review and meta-analysis. Helicobacter. 2021;26(4):e12816.","journal-title":"Helicobacter"},{"issue":"6","key":"2890_CR20","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/apt.13325","volume":"42","author":"Y Sakurai","year":"2015","unstructured":"Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T, et al. Acid-inhibitory effects of vonoprazan 20\u00a0mg compared with esomeprazole 20\u00a0mg or rabeprazole 10\u00a0mg in healthy adult male subjects - a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015;42(6):719\u201330.","journal-title":"Aliment Pharmacol Ther"},{"key":"2890_CR21","doi-asserted-by":"publisher","first-page":"881968","DOI":"10.3389\/fcimb.2022.881968","volume":"12","author":"Y Hu","year":"2022","unstructured":"Hu Y, Xu X, Ouyang YB, He C, Li NS, Xie C, et al. Altered gut microbiota and short-chain fatty acids after Vonoprazan-Amoxicillin Dual Therapy for Helicobacter pylori Eradication. Front Cell Infect Microbiol. 2022;12:881968.","journal-title":"Front Cell Infect Microbiol"},{"key":"2890_CR22","doi-asserted-by":"publisher","first-page":"8580","DOI":"10.1007\/s11356-019-07543-3","volume":"27","author":"S Mukherjee","year":"2020","unstructured":"Mukherjee S, Madathil SA, Ghatak S, Jahau L, Pautu JL, Zohmingthanga J, et al. Association of tobacco smoke\u2013infused water (tuibur) use by Mizo people and risk of Helicobacter pylori infection. Environ Sci Pollut Res Int. 2020;27:8580\u20135.","journal-title":"Environ Sci Pollut Res Int"},{"issue":"5","key":"2890_CR23","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/S0016-5085(17)30921-6","volume":"152","author":"CT Hu","year":"2017","unstructured":"Hu CT, Tung C, Lin CJ, Kuo IJ, Lin BR, Wang HL, et al. Efficacy of high-dose dual therapy versus bismuthcontaining quadruple therapy for first-line treatment of helicobacter pylori infection and an interim report of multi-center, randomized control study. Gastroenterology. 2017;152(5):182\u2013S183.","journal-title":"Gastroenterology"},{"issue":"6","key":"2890_CR24","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1093\/jac\/dkz046","volume":"74","author":"WC Tai","year":"2019","unstructured":"Tai WC, Liang CM, Kuo CM, Huang PY, Wu CK, Yang SC, et al. A 14\u00a0day esomeprazole-and amoxicillin-containing high-dose dual therapy regimen achieves a high eradication rate as first-line anti-helicobacter pylori treatment in Taiwan: a prospective randomized trial. J Antimicrob Chemother. 2019;74(6):1718\u201324.","journal-title":"J Antimicrob Chemother"},{"issue":"5","key":"2890_CR25","doi-asserted-by":"publisher","first-page":"e12717","DOI":"10.1111\/hel.12717","volume":"25","author":"W Gao","year":"2020","unstructured":"Gao W, Ye H, Deng X, Wang C, Xu Y, Li Y, et al. Rabeprazole-amoxicillin dual therapy as first-line treatment for H pylori eradication in special patients: a retrospective, real-life study. Helicobacter. 2020;25(5):e12717.","journal-title":"Helicobacter"},{"issue":"5","key":"2890_CR26","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1136\/gutjnl-2015-311019","volume":"65","author":"MP Dore","year":"2016","unstructured":"Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut. 2016;65(5):870\u20138.","journal-title":"Gut"},{"issue":"48","key":"2890_CR27","doi-asserted-by":"publisher","first-page":"7361","DOI":"10.3748\/wjg.14.7361","volume":"14","author":"AC Ford","year":"2008","unstructured":"Ford AC, Malfertheiner P, Giguere M, Santana J, Khan M, Moayyedi P. Adverse events with bismuth salts for Helicobacterpylori eradication: systematic review and meta-analysis. World J Gastroenterol. 2008;14(48):7361\u201370.","journal-title":"World J Gastroenterol"},{"issue":"6","key":"2890_CR28","doi-asserted-by":"publisher","first-page":"e751","DOI":"10.1097\/MJT.0000000000000389","volume":"24","author":"H Alkim","year":"2017","unstructured":"Alkim H, Koksal A, Boga S, Sen I, Alkim C. Role of bismuth in the eradication of Helicobacter pylori. Am J Ther. 2017;24(6):e751\u20137.","journal-title":"Am J Ther"},{"issue":"3","key":"2890_CR29","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1111\/j.1523-5378.2010.00758.x","volume":"15","author":"Q Sun","year":"2010","unstructured":"Sun Q, Liang X, Zheng Q, Liu W, Xiao S, Gu W, et al. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication. Helicobacter. 2010;15(3):233\u20138.","journal-title":"Helicobacter"},{"issue":"10058","key":"2890_CR30","doi-asserted-by":"publisher","first-page":"2355","DOI":"10.1016\/S0140-6736(16)31409-X","volume":"388","author":"JM Liou","year":"2016","unstructured":"Liou JM, Fang YJ, Chen CC, Bair MJ, Chang CY, Lee YC, et al. Taiwan Gastrointestinal Disease and Helicobacter Consortium. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial. Lancet. 2016;388(10058):2355\u201365.","journal-title":"Lancet"},{"issue":"4","key":"2890_CR31","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/hel.12126","volume":"19","author":"TA Attumi","year":"2014","unstructured":"Attumi TA, Graham DY. High-dose extended-release lansoprazole (dexlansoprazole) and amoxicillin dual therapy for Helicobacter pylori infections. Helicobacter. 2014;19(4):319\u201322.","journal-title":"Helicobacter"},{"issue":"30","key":"2890_CR32","first-page":"2108","volume":"92","author":"W Gao","year":"2012","unstructured":"Gao W, Cheng H, Hu FL, L\u00fc NH, Xie Y, Sheng JQ, et al. [Ilaprazole based bismuth-containing quadruple regimen for the first-line treatment of Helicobacter pylori infection: a multicenter, randomized, controlled clinical study]. Zhonghua Yi Xue Za Zhi. 2012;92(30):2108\u201312.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"24","key":"2890_CR33","doi-asserted-by":"publisher","first-page":"2899","DOI":"10.1097\/CM9.0000000000002546","volume":"135","author":"L Zhou","year":"2022","unstructured":"Zhou L, Lu H, Song Z, Lyu B, Chen Y, Wang J, on behalf of Helicobacter Pylori Study Group of Chinese Society of Gastroenterology, et al. 2022 chinese national clinical practice guideline on Helicobacter pylori eradication treatment. Chin Med J (Engl). 2022;135(24):2899\u2013910.","journal-title":"Chin Med J (Engl)"},{"issue":"14","key":"2890_CR34","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1097\/CM9.0000000000002289","volume":"135","author":"H Bi","year":"2022","unstructured":"Bi H, Chen X, Chen Y, Zhao X, Wang S, Wang J, et al. Efficacy and safety of high-dose esomeprazole\u2013amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial. Chin Med J (Engl). 2022;135(14):1707\u201315.","journal-title":"Chin Med J (Engl)"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02890-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-023-02890-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-023-02890-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,24]],"date-time":"2023-07-24T08:04:34Z","timestamp":1690185874000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcgastroenterol.biomedcentral.com\/articles\/10.1186\/s12876-023-02890-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,24]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["2890"],"URL":"https:\/\/doi.org\/10.1186\/s12876-023-02890-5","relation":{},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,24]]},"assertion":[{"value":"26 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study protocol was approved by the Clinical Ethics Committee of the Second Affiliated Hospital of Hainan Medical University and performed per Helsinki\u2019s Declaration (approval number: LW2022270). A written informed consent was obtained from all the participants and also from the legal guardians of the participants whose age was below 16 years of age. The trial registration number is ChiCTR2100052308.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}}],"article-number":"249"}}